Kaposi's sarcoma of lymph nodes
ICD-10 C46.3 is a billable code used to indicate a diagnosis of kaposi's sarcoma of lymph nodes.
Kaposi's sarcoma (KS) is a type of cancer that arises from the endothelial cells lining blood vessels and lymphatic vessels. It is characterized by the development of tumors that can appear as red, purple, or brown lesions on the skin, but it can also affect internal organs, including lymph nodes. KS is most commonly associated with immunocompromised states, particularly in individuals with HIV/AIDS. The lymph node involvement in KS can lead to lymphadenopathy, which may present as swollen lymph nodes that can be painful or asymptomatic. The pathophysiology of KS involves the infection of endothelial cells by Human Herpesvirus 8 (HHV-8), leading to abnormal proliferation and angiogenesis. Diagnosis is typically made through clinical evaluation, imaging studies, and biopsy of affected tissues. Treatment options for Kaposi's sarcoma of lymph nodes may include antiretroviral therapy (ART) for HIV-positive patients, chemotherapy, radiation therapy, and immunotherapy, depending on the extent of the disease and the patient's overall health status.
Detailed pathology reports, imaging studies, and treatment plans.
Patients presenting with skin lesions and lymphadenopathy, requiring biopsy and staging.
Ensure accurate staging and grading of KS for appropriate treatment coding.
HIV status, CD4 counts, and treatment history.
Management of HIV-positive patients with KS, requiring coordination of antiretroviral therapy.
Documenting the relationship between HIV and KS is crucial for accurate coding.
Used when a biopsy is performed to confirm KS diagnosis.
Pathology report must be included.
Oncology specialists should ensure accurate reporting of findings.
Kaposi's sarcoma is primarily caused by infection with Human Herpesvirus 8 (HHV-8), particularly in individuals with weakened immune systems, such as those with HIV/AIDS.
